Targovax Oy
🇫🇮Finland
- Country
- 🇫🇮Finland
- Ownership
- Subsidiary
- Established
- 2007-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.targovax.com
A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
- First Posted Date
- 2022-09-30
- Last Posted Date
- 2023-06-22
- Lead Sponsor
- Targovax Oy
- Registration Number
- NCT05561491
A Pilot Study of Sequential ONCOS-102, an Engineered Oncolytic Adenovirus Expressing GMCSF, and Pembrolizumab in Patients With Advanced or Unresectable Melanoma Progressing After Programmed Cell Death Protein 1 (PD1) Blockade
Phase 1
Completed
- Conditions
- Interventions
- First Posted Date
- 2016-12-28
- Last Posted Date
- 2021-11-08
- Lead Sponsor
- Targovax Oy
- Target Recruit Count
- 21
- Registration Number
- NCT03003676
- Locations
- 🇳🇴
Oslo University Hospital - The Norwegian Radium Hospital, Oslo, Norway
🇺🇸University of Maryland Comprehensive Cancer Center, Baltimore, Maryland, United States
🇺🇸Memorial Sloan Kettering Cancer Center, New York, New York, United States
A Randomised Phase II Open-label Study With a Phase Ib Safety lead-in Cohort of ONCOS-102, an Immune-priming GM-CSF Coding Oncolytic Adenovirus, and Pemetrexed/Cisplatin in Patients With Unresectable Malignant Pleural Mesothelioma
- First Posted Date
- 2016-08-26
- Last Posted Date
- 2020-10-08
- Lead Sponsor
- Targovax Oy
- Target Recruit Count
- 31
- Registration Number
- NCT02879669
- Locations
- 🇪🇸
Hospital Universitario Quirón, Barcelona, Spain
🇫🇷CHU de Rennes - Pontchaillou, Rennes, France
🇪🇸Hospital Universitario HM Sanchinarro, Madrid, Spain
ONCOS-102 (Previously CGTG-102) for Therapy of Advanced Cancers
- First Posted Date
- 2012-05-15
- Last Posted Date
- 2016-10-24
- Lead Sponsor
- Targovax Oy
- Target Recruit Count
- 12
- Registration Number
- NCT01598129
- Locations
- 🇫🇮
Docrates Hospital, Helsinki, Finland
© Copyright 2024. All Rights Reserved by MedPath